Cassava didn’t present at Guggenheim. This headline from Yahoo Finance sums up why SAVA rose: Cassava Sciences stock pops after rival experiences setback in Alzheimer’s research.
I guess the cabal has it in for AVXL but not for SAVA. Is there any other possible explanation, other than investors don’t believe in Anavex?